Trial Profile

Phase I/II Trial of BMS-986205 and Nivolumab as First or Second Line Therapy in Hepatocellular Carcinoma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Linrodostat (Primary) ; Nivolumab (Primary)
Indications Liver cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

01 Dec 2023 Results(n=8) describing the data of dose escalation cohort, published in the Investigational New Drugs
19 Aug 2023 Status changed from active, no longer recruiting to discontinued due to funding source decision to terminate study.
07 Jun 2022 Results (n=8) of the dose escalation cohort, presented at the 58th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com